Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?
In recent years, the clinical installation of immune checkpoint inhibitors (ICIs) has proven to be an exceptionally valuable addition to
oncological therapy, illustrating superior short- and long-term efficacy in challenging-to-treat malignancies and taking on an increasing
role across the majority of disease sites.
By Cynara Livera|2023-05-17T14:43:21+01:00February 15th, 2023|Comments Off on Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?